See related research by Sechterberger *et al*., <http://ccforum.com/content/17/2/R52>, and related research by Krinsley *et al*., <http://ccforum.com/content/17/2/R37>

Sechterberger and colleagues \[[@B1]\] recently reported a large single-center observational cohort study of the relationship of diabetic status to dysglycemia - hyperglycemia, hypoglycemia, and increased glycemic variability - and mortality in the critically ill. The online publication of their investigation came less than 2 weeks after that of a nearly identical study that I was privileged to lead and that involved 44,964 patients from 23 intensive care units (ICUs) in four continents \[[@B2]\]. The findings of the two investigations, which both appear in finalized form in this issue of *Critical Care*, are strikingly similar, a confirmation that strengthens the power of the conclusions of both studies. It may be time to change our glycemic control practice in the ICU - again!

The management of blood glucose (BG) in the critically ill became a topic of great interest following the publication of the landmark single-center surgical ICU study targeting euglyemia (80 to 110 mg/dL) in Leuven, Belgium, in 2001 \[[@B3]\]. This was truly the \'study that launched a thousand protocols\' and resulted in guidelines promoting \'tight\' control \[[@B4]\]. Nevertheless, a series of randomized interventional trials targeting euglyemia failed to corroborate the impressive findings of the initial study, culminating in the 6,104-patient NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation) trial \[[@B5]\] that suggested that a moderate glycemic target was preferable to \'tighter\' control. The pendulum then swung. New guidelines promoted much higher glycemic target ranges (140 to 180 or even 140 to 200 mg/dL) for all patients in the ICU \[[@B6]\].

What explains the inconsistent results of the interventional trials of glycemic control in the critically ill? Whereas hyperglycemia was the target of the interventional trials, hypoglycemia was their unifying complication. Hypoglycemia was found to be independently associated with increased risk of mortality in the major interventional trials \[[@B7],[@B8]\] and in several observational cohort studies \[[@B9]-[@B11]\]. Glucose variability was not even considered in the design and analysis of the interventional trials. Nevertheless, high levels of this third \'domain\' of glycemic control were subsequently found to be independently associated with increased risk of mortality in the Leuven studies \[[@B7]\] and in several retrospective series \[[@B12]-[@B14]\]. Finally, the independent role of diabetic status on modulating these relationships has emerged as another crucial factor \[[@B15]\].

The new \'three domains\' study by Sechterberger and colleagues \[[@B1]\] evaluated 10,320 patients admitted to a single 24-bed medical-surgical ICU between 2004 and 2011. The target glucose range was initially 72 to 136 mg/dL. After the publication of the NICE-SUGAR trial, the target was changed to 90 to 162 mg/dL. Notably, in keeping with routine clinical practice, the same target was applied to all patients regardless of diagnosis and diabetic status. A U-shaped curve described the relationship of hyperglycemia to mortality among non-diabetics, but there was no consistent relationship between mean BG and mortality among those with diabetes. Hypoglycemia, defined as a BG of not more than 40 mg/dL, was independently associated with increased risk of mortality in both groups, as was \'low glucose\', idiosyncratically defined as a BG of 41 to 85 mg/dL. Finally, increasing glycemic variability, defined by using the metric of mean absolute glucose change, was independently associated with increased risk of mortality among non-diabetics but not among diabetics. Every one of these major conclusions confirmed the findings of our study, published online by the same journal 11 days earlier \[[@B2]\]!

This convergence has potential implications for clinical practice. The era of \'one size fits all\' in regard to glycemic targets in the critically ill has likely ended. In my own ICU, I am preparing my nurses for the task of developing a range of glycemic targets stratified by (a) diagnosis (the earlier study \[[@B2]\], but not the current one \[[@B1]\], evaluated differences between medical and surgical patients), (b) diabetic status, and (c) and among the patients with diabetes, further stratified by the intensity of preadmission glycemic control, based on HgbA1c levels \[[@B16]\]. Perhaps I should make sure I am on vacation on the day that six different protocols are rolled out!

Furthermore, the two \'three domains\' studies \[[@B1],[@B2]\] provide a clarion call for the development and clinical implementation of new technologies to monitor BG. Quite simply, intermittent monitoring is not up to the task, a conclusion reached last year by a consensus panel convened at the 32nd International Symposium on Intensive Care and Emergency Medicine \[[@B17]\]. We will be asking our nurses to (a) target a discrete BG range by using insulin, (b) avoid hypoglycemia, and (c) minimize glucose variability. We now have abundant data demonstrating that this cannot be accomplished safely or effectively by using meters, strips, and blood gas analyzers measuring BG at the (Herculean) rate of 13 tests per 24 hours in this study \[[@B1]\] or the three to nine tests per 24 hours (perhaps a more realistic rate, given the 5 to 10 minutes that each measurement takes, from data acquisition to treatment decision) among the centers participating in the earlier study \[[@B2]\]. Moreover, we can be certain that these monitoring frequencies do not detect every episode of dysglyemia that occurs in our patients! Successful management of all three domains of glycemic control will require the use of continuous or nearly continuous technologies \[[@B18]\]. Fortunately, this era is about to begin.
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